Provided by Tiger Trade Technology Pte. Ltd.

InMed Pharmaceuticals Inc

1.36
+0.03002.26%
Post-market: 1.35-0.0100-0.74%19:50 EDT
Volume:56.13K
Turnover:78.91K
Market Cap:7.47M
PE:-0.44
High:1.44
Open:1.35
Low:1.35
Close:1.33
52wk High:2.40
52wk Low:0.5750
Shares:5.49M
Float Shares:2.15M
Volume Ratio:2.26
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1200
EPS(LYR):-8.3630
ROE:-156.77%
ROA:-66.46%
PB:6.95
PE(LYR):-0.16

Loading ...

ADAR1 Capital Management Reports $14,530 InMed Pharmaceuticals Common Shares Purchase

Reuters
·
Oct 09

ADAR1 Capital Management Reports $56,041 InMed Pharmaceuticals Common Share Purchase

Reuters
·
Oct 06

InMed receives Nasdaq notification from listing qualifications department

TIPRANKS
·
Sep 19

InMed Gets NASDAQ Notice After Stockholders’ Equity Falls Below $2.5 Million Minimum

Reuters
·
Sep 19

InMed Says Mentari Merger to Deliver USD 490 Million in Gross Proceeds, Restore NASDAQ Equity Compliance

Reuters
·
Sep 19

ADAR1 Capital Management Reports $117,700 InMed Pharma Common Share Purchase

Reuters
·
Sep 17

InMed FY26 Net Loss Widens to Us$12.9 Million; Discontinued-Ops Sales Drop 36% to Us$3.2 Million

Reuters
·
Sep 10

Mentari Therapeutics Merger with Inmed Set to Close Ahead of USD 200 Million Private Placement

Reuters
·
Jul 22

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

THOMSON REUTERS
·
Jul 22

ADAR1 Capital Acquires 1,000 Inmed Common Shares Worth $1,555

Reuters
·
Jul 18

Vivo Opportunity Reports USD 32,319 Purchase of Inmed Common Shares

Reuters
·
Jul 17

Inmed Amends Merger Deal with Mentari, Files S-4 Registration Statement

Reuters
·
Jul 11

InMed Pharmaceuticals amends merger pact with Mentari Therapeutics

TIPRANKS
·
Jul 07

Vivo Opportunity Reports $9,963 Purchase of Inmed Pharma Common Shares

Reuters
·
Jul 03

Vivo Opportunity reports $371,785 purchase of InMed Pharma common shares

Reuters
·
Jun 11

InMed Pharmaceuticals files Form 3 as Vivo Opportunity discloses beneficial ownership of 541,752 shares

Reuters
·
Jun 11

InMed Pharmaceuticals regains Nasdaq compliance on $1 minimum bid price rule

Reuters
·
Jun 10

InMed regains compliance with Nasdaq continued listing requirements

TIPRANKS
·
Jun 05

InMed Pharma releases INM-089 age-related macular degeneration presentation

Reuters
·
Jun 03

ADAR1 Capital Management acquires 468,551 InMed common shares worth $742,290

Reuters
·
May 22